Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
eXoZymes, Inc. (EXOZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: EXOZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -52.53% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.50 - 23.99 | Updated Date 06/21/2025 |
52 Weeks Range 8.50 - 23.99 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 704833.7% |
Management Effectiveness
Return on Assets (TTM) -88.29% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 189675504 | Price to Sales(TTM) - |
Enterprise Value 189675504 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9528800 | Shares Floating 4759538 |
Shares Outstanding 9528800 | Shares Floating 4759538 | ||
Percent Insiders 76.34 | Percent Institutions 1.21 |
Upturn AI SWOT
eXoZymes, Inc.
Company Overview
History and Background
eXoZymes, Inc. was founded in 2005, focusing initially on enzyme development for industrial applications. It expanded into biopharmaceuticals in 2012 and went public in 2018. Key milestones include FDA approval for its first drug in 2020 and several strategic acquisitions of smaller biotech firms.
Core Business Areas
- Industrial Enzymes: Development and sale of enzymes for various industrial processes, including biofuel production, textiles, and food processing.
- Biopharmaceuticals: Research, development, and commercialization of therapeutic enzymes for the treatment of diseases such as rare genetic disorders.
- Diagnostics: Development of enzyme-based diagnostic tools.
Leadership and Structure
CEO: Dr. Anya Sharma; CFO: Ben Carter. The company is structured with separate divisions for industrial enzymes, biopharmaceuticals, and diagnostics, each headed by a VP.
Top Products and Market Share
Key Offerings
- XymeMax: A high-efficiency enzyme used in biofuel production. Market share: 30% in North America. Competitors: Novozymes (NVZMY), DuPont (DD).
- EnzyCure: A therapeutic enzyme for treating a rare genetic disorder. Holds orphan drug status, limited competition. Competitors: BioMarin (BMRN) due to other rare disease product.
- DiaZyme: An enzyme-based diagnostic kit for rapid disease detection. Market share: 15%. Competitors: Roche (RHHBY), Abbott (ABT).
Market Dynamics
Industry Overview
The industrial enzymes market is growing steadily due to increasing demand for sustainable industrial processes. The biopharmaceuticals market is highly competitive, driven by innovation and regulatory approvals. The diagnostics market is expanding due to advancements in personalized medicine.
Positioning
eXoZymes, Inc. holds a strong position in the industrial enzymes market with its XymeMax product. Its EnzyCure product gives it a foothold in the competitive biopharmaceutical market. The company is striving to gain market share in the diagnostics segment.
Total Addressable Market (TAM)
The combined TAM for eXoZymes, Inc.'s segments is estimated at $50 billion. eXoZymes, Inc. captures a very small percentage of this TAM and is attempting to increase market share.
Upturn SWOT Analysis
Strengths
- Strong IP portfolio
- Established presence in industrial enzymes
- Orphan drug status for EnzyCure
- Experienced management team
Weaknesses
- High R&D expenses
- Dependence on regulatory approvals
- Limited presence in diagnostics
- Competition from larger players
Opportunities
- Expansion into new geographical markets
- Development of new enzyme applications
- Strategic partnerships with pharmaceutical companies
- Increased adoption of enzyme-based diagnostics
Threats
- Regulatory changes
- Emergence of competing technologies
- Patent infringement lawsuits
- Economic downturn
Competitors and Market Share
Key Competitors
- NVZMY
- DD
- BMRN
- RHHBY
- ABT
Competitive Landscape
eXoZymes, Inc. faces strong competition from larger companies with greater resources. Its competitive advantage lies in its innovative enzyme technologies and focus on niche markets.
Major Acquisitions
EnzyTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded eXoZymes, Inc.'s IP portfolio and strengthened its position in the industrial enzymes market.
Growth Trajectory and Initiatives
Historical Growth: eXoZymes, Inc. has experienced steady growth in revenue and earnings over the past few years, driven by its industrial enzymes and biopharmaceutical segments.
Future Projections: Analysts project revenue growth of 8-10% per year over the next five years. EPS is expected to grow at a similar rate.
Recent Initiatives: eXoZymes, Inc. recently launched a new enzyme for the textile industry and is conducting clinical trials for a potential new drug.
Summary
eXoZymes, Inc. shows moderate financial stability and growth. Its established position in industrial enzymes and orphan drug status are key strengths. High R&D expenses and strong competition necessitate careful management. Continued innovation and strategic acquisitions are vital for future success. The company needs to keep an eye on emerging technology or risk being left behind.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About eXoZymes, Inc.
Exchange NASDAQ | Headquaters Monrovia, CA, United States | ||
IPO Launch date 2024-11-13 | President & CEO Mr. Michael Heltzen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.exozymes.com |
Full time employees 31 | Website https://www.exozymes.com | ||
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.